HOME>HOME>Sustainability>Our Sustainability>Various Contrasting Tables

Various Contrasting Tables

Sustainability-related information and comparison with various guidelines.


Core subjects and issues Public information on ASKA Pharmaceutical HD's Efforts
6.2 Organizational Governance
6.3 Human Rights 6.3.3:Due Diligence
6.3.4:Human Rights Risk Situations
6.3.5:Avoidance of Complicity
6.3.6:Resolving Grievances
6.3.7:Discrimination and Vulnerable Groups
6.3.8:Civil and Political Rights
6.3.9:Economic, Social and Cultural Rights
6.3.10:Fundamental Principles and Rights at Work
6.4 Labour Practices 6.4.3:Employment and Employment Relationships
6.4.4:Conditions of Work and Social Protection
6.4.5:Social Dialogue
6.4.6:Health and Safety at Work
6.4.7:Human Development and Training in the Workplace
6.5 The Environment 6.5.3:Prevention of Pollution
6.5.4:Sustainable Resource Use
6.5.5:Climate Change Mitigation and Adaptation
6.5.6:Protection of the Environment, Biodiversity and Restoration of Natural Habitats
6.6 Fair Operating Practices 6.6.3:Anti-corruption
6.6.4:Responsible Political Involvement
6.6.5:Fair Competition
6.6.6:Promoting Social Responsibility in the Value Chain
6.6.7:Respect for Property Rights
6.7 Consumer Issues 6.7.3:Fair Marketing, Factual and Unbiased Information and Fair Contractual Practices
6.7.4:Protecting Consumers' Health and Safety
6.7.5:Sustainable Consumption
6.7.6:Consumer Service, Support, and Complaint and Dispute Resolution
6.7.7:Consumer Data Protection and Privacy
6.7.8:Access to Essential Services
6.7.9:Education and Awareness
6.8 Community Involvement and Development 6.8.3:Community Involvement
6.8.4:Education and Culture
6.8.5:Employment Creation and Skills Development
6.8.6:Technology Development and Access
6.8.7:Wealth and Income Creation
6.8.9:Social Investment

GRI Standards

Universal Disclosures

Disclosure Website Pages
Integrated Report Annual Security Report ESG Data Book
GRI 2:General disclosure 2021 The organization and its reporting practices
2-1 Organizational profile P59 P1
2-2 Entities included in the organization’s sustainability reporting P22-P33 P4-P7
2-3 Reporting period, frequency and contact point P1
* Issued in September 2023 (Issued annualy)
2‑4 Restatements of information
2‑5 External assurance
GRI 2:General disclosure 2021 Activities and workers
2‑6 Activities, value chain and other business relationships P22-P33 P8-P23
2‑7 Employees P59 P6ーP7 P11-P14
2‑8 Workers who are not employees
GRI 2:General disclosure 2021 Governance
2‑9 Governance structure and composition P46-P53 P30-P44 P22-P27
2‑10 Nomination and selection of the highest governance body P46-P53 P30-P44 P23
2‑11 Chair of the highest governance body P46-P53 P30-P44 P23
2‑12 Role of the highest governance body in overseeing the management of impacts P46-P53 P30-P44 P21
2‑13 Delegation of responsibility for managing impacts
2‑14 Role of the highest governance body in sustainability reporting P46-P49 P9-P10
2‑15 Conflicts of interest P26
2‑16 Communication of critical concerns P46-P51 P31 P25
2‑17 Collective knowledge of the highest governance body P44-P53 P9/P40 P21
2‑18 Evaluation of the performance of the highest governance body P44-P53 P9/P40 P21
2‑19 Remuneration policies P49-P50 P39-P40 P24
2‑20 Process to determine remuneration P49-P50 P39-P40 P24
2‑21 Annual total compensation ratio P49-P50 P39-P40 P24
GRI 2:General disclosure 2021 Strategy, policies and practices
2‑22 Statement on sustainable development strategy P12-P16 P9
2‑23 Policy commitments P16-P17
2‑24 Embedding policy commitments P16-P17 P9-P14
2‑25 Processes to remediate negative impacts
2‑26 Mechanisms for seeking advice and raising concerns P46-P51 P30-P31 P25-P26
2‑27 Compliance with laws and regulations P51 P30-P31 P25-P26
2‑28 Membership associations P27
GRI 2:General disclosure 2021 Stakeholder engagement
2‑29 Approach to stakeholder engagement P46
P30 P20
2‑30 Collective bargaining agreements P16 P11-P14 P11
GRI 3: Material topics 2021 Disclosures on material topics
3‑1 Process to determine material topics P16 P9
3‑2 List of material topics P17
3‑3 Management of material topics P17 P9-P11


Disclosure Website Page
Integrated Report Annual Securities Report ESG Data Book
GRI201:Economic Performance 2016
201-1 Direct economic value generated and distributed P56-P57 P1-P2
201-2 Financial implications and other risks and opportunities due to climate change P55 P10-P11
201-3 Defined benefit plan obligations and other retirement plans P67-P68
201-4 Financial assistance received from government
GRI202:Market Presence 2016
202-1 Ratios of standard entry level wage by gender compared to local minimum wage
202-2 Proportion of senior management hired from the local community
RI203:Indirect Economic Impacts 2016
203-1 Infrastructure investments and services supported P20-P29 P24 P20
203-2 Significant indirect economic impacts
GRI204:Procurement Practices 2016
204-1 Proportion of spending on local suppliers
GRI205:Anti-corruption 2016
205-1 Operations assessed for risks related to corruption
205-2 Communication and training about anti-corruption policies and procedures P26
205-3 Confirmed incidents of corruption and actions taken and procedures P26
GRI206:Anti-competitive Behavior 2016
206-1 Legal actions for anti-competitive behavior, anti-trust, and monopoly practices and procedures
GRI207:Tax 2019
207-1 Approach to tax P26
207-2 Tax governance, control, and risk management P26
207-3 Stakeholder engagement and management of concerns related to tax
207-4 Country-by-country reporting


Disclosure Website Page
Integrated Report Annual Securities Report ESG Data Book
GRI301:Materials 2016
301-1 Materials used by weight or volume P8-P9
301-2 Recycled input materials used P8
301-3 Reclaimed products and their packaging materials
GRI302:Energy 2016
302-1 Energy consumption within the organization P3
302-2 Energy consumption outside of the organization
302-3 Energy intensity
302-4 Reduction of energy consumption P54 P3
302-5 Reduction in energy requirements of products and services
GRI303:Water and Effluents 2018
303-1 Interactions with water as a shared resource P55 P4-P6
303-2 Management of water discharge-related impacts P55 P7
303-3 Water withdrawal P4-P6
303-4 Water discharge P4-P6
303-5 Water consumption P4-P6
GRI304:Biodiversity 2016
304-1 Operational sites owned, leased, managed in, or adjacent to, protected areas and areas of high biodiversity value outside protected areasOperational sites owned, leased, managed in, or adjacent to, protected areas and areas of high biodiversity value outside protected areas
304-2 Significant impacts of activities, products, and services on biodiversity
304-3 Habitats protected or restored P17/P55
304-4 IUCN Red List species and national conservation list species with habitats in areas affected by operations
GRI305:Emissions 2016
305-1 Direct (Scope 1) GHG emissions P10-P11 P3
305-2 Energy indirect (Scope 2) GHG emissions P10-P11 P3
305-3 Other indirect (Scope 3) GHG emissions
305-4 GHG emissions intensity
305-5 Reduction of GHG emissions P54 P10-P11 P3
305-6 Emissions of ozone-depleting substances (ODS)
305-7 Nitrogen oxides (NOX), sulfur oxides (SOX), and other significant air emissions P55 P4
GRI306:Effluents and Waste 2020
306-1 Waste generation and significant waste-related impacts P55 P7
306-2 Management of significant waste-related impacts P55 P7
306-3 Waste generated P55 P7
306-4 Waste diverted from disposal
306-5 Waste directed to disposal P55 P7
GRI307:Environmental Compliance 2016
307-1 Non-compliance with environmental laws and regulations※2 P2
GRI308:Supplier Environmental Assessment 2016
308-1 New suppliers that were screened using environmental criteria
308-2 Negative environmental impacts in the supply chain and actions taken
*2 No environment-related accidents occurred in FY2022.


Disclosure Website Page
Integrated Report Annual Securities Report ESG Data Book
GRI401:Employment 2016
401-1 New employee hires and employee turnover P7 P12-P13
401-2 Benefits provided to full-time employees that are not provided to temporary or part-time employees
401-3 Parental leave P17/P36 P6/P13 P14
GRI402:Labor/Management Relations 2016
402-1 Minimum notice periods regarding operational changes
GRI403: Occupational Health and Safety 2018
403-1 Occupational health and safety management system P37 P13 P19
403-2 Hazard identification, risk assessment, and incident investigation P18-P19
403-3 Occupational health services P37 P13 P19
403-4 Worker participation, consultation, and communication on occupational health and safety P37 P13 P18
403-5 Worker training on occupational health and safety P37/P39 P13
403-6 Promotion of worker health P37-P38 P13 P18
403-7 Prevention and mitigation of occupational health and safety impacts directly linked by business relationships
403-8 Workers covered by an occupational health and safety management system P37
403-9 Work-related injuries P19
403-10 Work-related ill health P19
GRI404:Training and Education 2016
404-1 Average hours of training per year per employee P15
404-2 Programs for upgrading employee skills and transition assistance programs P17、P34-P35 P11-P12 P15-P17
404-3 Percentage of employees receiving regular performance and career development reviews
GRI405:Diversity and Equal Opportunity 2016
405-1 Diversity of governance bodies and employees P36 P12 P14
405-2 Ratio of basic salary and remuneration of women to men P12
GRI406:Non-discrimination 2016
406-1 Incidents of discrimination and corrective actions taken
GRI407:Freedom of Association and Collective Bargaining 2016
407-1 Operations and suppliers in which the right to freedom of association and collective bargaining may be at risk P11
GRI408:Child Labor 2016
408-1 Operations and suppliers at significant risk for incidents of forced or compulsory labor
GRI409:Forced or Compulsory Labor 2016
409-1 Operations and suppliers at significant risk for incidents of forced or compulsory labor
GRI410:Security Practices 2016
410-1 Security personnel trained in human rights policies or procedures
GRI411:Rights of Indigenous Peoples 2016
411-1 Incidents of violations involving rights of indigenous peoples
GRI412:Human Rights Assessment 2016
412-1 Operations that have been subject to human rights reviews or impact assessments
412-2 Employee training on human rights policies or procedures
412-3 Significant investment agreements and contracts that include human rights clauses or that underwent human rights screening
GRI413:Local Communities 2016
413-1 Operations with local community engagement, impact assessments, and development programs P43/P58 P20
413-2 Operations with significant actual and potential negative impacts on local communities
GRI414:Supplier Social Assessment 2016
414-1 New suppliers that were screened using social criteria
414-2 Negative social impacts in the supply chain and actions taken
GRI415:Public Policy 2016
415-1 Political contributions
GRI416:Customer Health and Safety 2016
416-1 Assessment of the health and safety impacts of product and service categories P42
416-2 Incidents of non-compliance concerning the health and safety impacts of products and services
GRI417:Marketing and Labeling 2016
417-1 Requirements for product and service information and labeling
417-2 Incidents of non-compliance concerning product and service information and labeling
417-3 Incidents of non-compliance concerning marketing communications
GRI418:Customer Privacy 2016
418-1 Substantiated complaints concerning breaches of customer privacy and losses of customer data P16 P15 P25
GRI419:Socioeconomic Compliance 2016
419-1 Non-compliance with laws and regulations in the social and economic area

United Nation Global Compact

The Ten Principles of the UN Global Compact Website Page
Integrated Report Annual Securities Report ESG Data Book
Human rights Principle 1 Businesses should support and respect the protection of internationally proclaimed human rights; and P11/P19
Principle 2 make sure that they are not complicit in human rights abuses. P11/P19
Labour Principle 3 Businesses should uphold the freedom of association and the effective recognition of the right to collective bargaining; P11
Principle 4 the elimination of all forms of forced and compulsory labour;
Principle 5 the effective abolition of child labour; and
Principle 6 the elimination of discrimination in respect of employment and occupation. P11/P19
Environment Principle 7 Businesses should support a precautionary approach to environmental challenges; P54-P55 P9-P10 P2-P10
Principle 8 undertake initiatives to promote greater environmental responsibility; and P54-P55 P9-P10 P2-P10
Principle 9 encourage the development and diffusion of environmentally friendly technologies.
Anti-corruption Principle 10 Businesses should work against corruption in all its forms, including extortion and bribery. P26


Goal Specific efforts Website Page
Integrated Report Annual Securities Report ESG Data Book
3. Good health and well-being
  • A wide variety of hormonal products in the field of obstetrics and gynecology
  • Pharmaceuticals for the treatment of hepatic encephalopathy, a rare disease
  • Thyroid hormone preparations that have been used for about 100 years
  • Highly accurate LC-MS/MS sample measurement using proprietary technology
  • Health management
5. Gender equality
  • Oral and emergency contraceptives
  • Uterine fibroids and endometriosis agent
  • Dysmenorrhea agent
  • Fertility Agents
  • Eclampsia control and agent
  • Highly accurate steroid hormone measurement for preventive medicine and improvement of unwellness
  • Location-specific medical representative system
  • Telecommuting system
  • Granting of annual leave in increments of hours
  • Introduced pioneering hourly "child nursing care leave and nursing care leave" program
  • Paid childcare leave
  • Target for male employees taking childcare leave: 100%
P11-P13 P14
7. Affordable and clean energy
  • Promote energy conservation activities
  • Reduction of greenhouse gas emissions (conversion from heavy oil to city gas)
  • Establishment and operation of environmental management systems, etc.
  • Reduce unit energy consumption of all group companies by 1% or more compared to the previous year
P10-P11 P2-P10
12. Responsible consumption and production
  • Ensure appropriate inventory by utilizing our own factories, contract manufacturers, and external warehouses
  • Operation of quality systems in pharmaceuticals (management review with management participation)
  • Steady implementation of risk management plans for ethical pharmaceuticals, etc.
P8-P9 P1-P27
13. Climate action
  • Promote energy conservation activities
  • Reduction of greenhouse gas emissions (conversion from heavy oil to city gas)
  • Establishment and operation of environmental management systems, etc.
  • Reduce unit energy consumption of all group companies by 1% or more compared to the previous year
P10-P11 P2-P10
14. Life below water
  • A wide variety of reproductive hormones
  • Oxytocin Injection Solution for Veterinary Use
  • Mixed feed (Best Balance Series), etc.
P10-P11 P2-P10
15. Life on land
  • A wide variety of reproductive hormones
  • Oxytocin Injection Solution for Veterinary Use
  • Mixed feed (Best Balance Series), etc.
P10-P11 P2-P10
16. Peace justice and strong institutions
  • Ensure substantial equality of shareholders
  • Fostering a corporate culture and climate that respects sound business ethics
  • Ensuring Transparency
  • Effective supervision of directors
  • Constructive dialogue with shareholders
17. Partnerships for the goals
  • Enhancement of Testing Technology and Drug Discovery Functions in Shonan iPark through Collaboration with Other Companies
  • Addition of pediatric dosage and indication for existing pharmaceuticals, etc.
  • Veterinary pharmaceuticals developed from ethical pharmaceuticals


Safety of Clinical Trial Participants Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials HC-BP-210a.1
Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI) HC-BP-210a.2
  • Integrated Report2023: P42
Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries HC-BP-210a.3
  • No business in developing countries
Access to Medicines Description of actions and initiatives to promote access to healthcare products for priority diseases and in priority countries as defined by the Access to Medicine Index HC-BP-240a.1
  • No business in priority countries
List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP) HC-BP-240a.2
Afordability & Pricing Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period HC-BP-240b.1
  • Not disclosed
Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year HC-BP-240b.2
  • No business in U.S.
Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year HC-BP-240b.3
  • Product: LUTEUM
    (1)NHI Price: 541.90
    (2)Net Price: Not disclosed
Drug Safety List of products listed in the Food and Drug Administration’s (FDA) MedWatch Safety Alerts for Human Medical Products database HC-BP-250a.1
Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System HC-BP-250a.2
Number of recalls issued, total units recalled HC-BP-250a.3
Total amount of product accepted for take-back, reuse, or disposal HC-BP-250a.4
Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type HC-BP-250a.5
Counterfeit Drugs Description of methods and technologies used to maintain trace ability of products throughout the supply chain and prevent counterfeiting HC-BP-260a.1
Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products HC-BP-260a.2
Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products HC-BP-260a.3
Ethical Marketing Total amount of monetary losses as a result of legal proceedings associated with false marketing claims HC-BP-270a.1
Description of code of ethics governing promotion of off-label use of products HC-BP-270a.2
Employee Recruitment, Development & Retention Discussion of talent recruitment and retention efforts for scientists and research and development personnel HC-BP-330a.1
  • Not disclosed
(1) Voluntary and (2) involuntary turn over rate for: (a) executives/seniormanagers, (b) mid-level managers, (c) professionals, and (d) all others HC-BP-330a.2
  • Annual Securities Report: P7
SupplyChain Management Percentage of (1) entity's facilities and (2) Tier 1 suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients HC-BP-430a.1
Business Ethics Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery HC-BP-510a.1
  • ESG Data Book: P26
Description of code of ethics governing interactions with health care professionals HC-BP-510a.2

Number of patients treated HC-BP-000.A
Number of drugs (1) in portfolio and (2) in research and development (Phases1-3) HC-BP-000.B